Watch for Amputation Warnings With Diabetes Med Invokana

July 2017

A new warning about amputation with canagliflozin (Invokana, etc) will have patients asking about the safety of SGLT2 inhibitors.

This is the latest in a growing list of flozin concerns...ketoacidosis, acute kidney injury, UTIs, yeast infections, etc.

Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Diabetes Watch for Amputation Warnings With Diabetes Med Invokana
Statins Re-Evaluate Statin Use in Older Patients WithOUT CV Disease
Corticosteroids Know the Risks and Benefits of Short-Course Steroids
Inhalers Be Prepared to Switch Patients to New Fluticasone/Salmeterol Inhalers
Heart Failure Don't Jump to Newer Drugs for Systolic Heart Failure
Osteoporosis Stick With Bisphosphonates First-Line for Most Postmenopausal Women
Transdermal Patches Help Avoid Common Errors With Transdermal Patches
Anticoagulants Double-Check Dosing of Direct Oral Anticoagulants (DOACs) in Certain Patients
UTIs Compare Options for Preventing Recurrent UTIs
Parkinson Disease Consider Xadago a Me-Too MAO-B Inhibitor for Parkinson's Disease
Musculoskeletal Sort Through Options for Treating Nocturnal Leg Cramps

Watch for Amputation Warnings With Diabetes Med Invokana

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents